BIOSKETCHES

Co-Chairs

Elaina Kenyon

EPA NHEERL

Elaina M. Kenyon is a Research Toxicologist and principle investigator in the Pharmacokinetics Branch of the Integrated Systems Toxicology Division within the National Health and Environmental Effects Research Laboratory of the U.S. Environmental Protection Agency. Her research interests are in the general areas of xenobiotic metabolism and disposition, in vivo to in vitro extrapolation (IVIVE) and development and evaluation of physiologically based pharmacokinetic models with an emphasis on metals and volatile organic contaminants. Since coming to EPA in 1995, her research has focused on these areas for contaminants of concern in drinking water. Immediately prior to joining the U.S. EPA, Dr. Kenyon was a postdoctoral fellow at the Chemical Industry Institute of Toxicology. She received her Ph.D. from the University of Massachusetts in 1990 and currently serves on the Scientific Advisory Board for toxic air pollutants for the state of North Carolina, the Toxicology Advisory Board for the Art and Creative Materials Institute, and the editorial board of the journal Toxicology.

Gary Ginsberg

Connecticut Department of Public Health

Dr. Ginsberg is a toxicologist at the Connecticut Department of Public Health within the Division of Environmental and Occupational Health Assessment. He is responsible for human health risk assessments conducted within the state government. Dr. Ginsberg serves as adjunct faculty at the Yale School of Public Health and is an Assistant Clinical Professor at the University of Connecticut School of Community Medicine. He is currently a member of the National Academy of Sciences committee reviewing inorganic arsenic and served on two previous NAS committees (Human Biomonitoring, 2007; USEPA Risk Methods which produced Science and Decisions, 2009). He was first author of a manuscript that won best paper of the year award from the Society of Toxicology Risk Assessment Specialty Section, 2009. Dr. Ginsberg was a member of USEPA's Children's Health Protection Advisory Committee until 2009 and is currently a member of USEPA's Science Advisory Board. He has participated on expert review panels for state governments in Minnesota, New Jersey, California and Massachusetts. He was an Oak Ridge Institute for Science and Education (ORISE) fellow with USEPA's National Center for Environmental Assessment from 2010 to 2012. He has published in the areas of early life stage vulnerability, pharmacokinetic modeling, genetic polymorphisms, metabolism in aging populations, fish consumption advisories and environmental risk assessment. Dr. Ginsberg's toxicology experience has involved a variety of settings: basic research, teaching, working within the pesticide and consulting industries, and now working in public health. Dr. Ginsberg is also co-author of a book on toxics for the lay public, "What's Toxic, What's Not:" Berkley Books, December 2006.

Panelists

Kim Barrett

University of California – San Diego

Dr. Kim Barrett, a native of the United Kingdom, obtained her B.Sc. and Ph.D. from the Department of Chemistry at University College London. Following a post-doctoral fellowship at the National Institutes of Health, she joined the faculty of UCSD School of Medicine in 1985, and rose to her current rank of Professor of Medicine in 1996. In 2006, she also assumed the role of Dean of Graduate Studies for the campus as a whole. Her research interests center on the normal and abnormal physiology of the intestinal epithelium and their relevance to a variety of digestive diseases including inflammatory bowel diseases, infectious diarrheal diseases, and peptic ulcer disease. She is the author or editor of several books and monographs and more than two hundred peer-reviewed journal articles, book chapters, and reviews on these and related topics. Dr. Barrett has received a number of honors for her research, including the Bowditch and Davenport Lectureships of the American Physiological Society, and being awarded the degree of Doctor of Medical Science, honoris causa, by Queens University Belfast. She has also been highly active in professional societies and in scholarly editing. She is currently serving as President of the American Physiological Society and is Deputy Editor-in-Chief (for the Americas) of the Journal of Physiology.

Max Costa

New York University

Dr. Costa received his B.S. from Georgetown University in 1974 and his Ph.D. in Pharmacology in 1976 from the University of Arizona Medical School. During his undergraduate training, Dr. Costa worked full time at the National Institutes of Health in Dr. Kaufman's and Dr. Gallo's labs. In 1977 Dr. Costa did postdoctoral training in radiation oncology at the University of Arizona and then took a position as an Assistant Professor of Laboratory Medicine at the University of Connecticut Medical School for two years. In 1979 he moved to Texas A&M Medical School's Department of Pharmacology for one year and then took a position as an Assistant Professor of Pharmacology at the University of Texas Medical School at Houston, where he became Professor with tenure in 1985. In 1985 he moved to NYU School of Medicine, Department of Environmental Medicine as Professor and Deputy Director. In 1993, following a three-year international search, he was appointed Professor and Chair of the Department of Environmental Medicine at NYU as well as a Professor in the Department of Pharmacology. Dr. Costa is Director of the Environmental and Molecular Carcinogenesis Program for the NYU Cancer Institute's NIH Cancer Center Support Grant and Director of the NIEHS Center Grant in Environmental Health Sciences. Dr. Costa has authored more than 350 publications.

John Crison
Bristol-Myers Squibb

John Crison is a Research Fellow at Bristol-Myers Squibb with twenty five years' experience in small and large molecule formulation research and development. Prior to BMS, John has held positions in Biopharmaceutics and drug delivery for large Pharma and Biotech, as well as software product development for the pharmaceutical industry. His experience includes both immediate and modified release dosage forms, dissolution testing and pharmacokinetic and pharmacodynamic modeling, with extensive theoretical and practical experience in the application of in vivo, in vitro and in silico models for biopharmaceutical evaluation of compounds. John contributed to the FDA Guidance of a Biopharmaceutical Classification System (BCS) for establishing in vitro tests to waive in vivo bioequivalence tests and has applied this expertise in regulatory guidance for bioequivalence, biowaivers, dissolution method development, and establishing in vitro-in vivo correlations. John received his B.S., M.S. and Ph.D. degrees in Pharmacy and Pharmaceutics from the University of Michigan and has held adjunct faculty position at Michigan and also at the University of the Pacific and Albany College of Pharmacy. He is active in AAPS and has held leadership positions in several focus groups.

Silvio De Flora
University of Genoa

Dr. Silvio De Flora received his MD in 1966 and in the same year became an Assistant Professor at the School of Medicine of the University of Genoa (Italy). In 1975 he became a Full Professor and Chairman and was made Professor Emeritus in 2013. Dr. De Flora served as Director of the Institute of Hygiene and Preventive Medicine from 1986-1998 and Director of Health Sciences from 1999-2005 and 2010-2012. He is the author of over 442 scientific papers and has published in collaboration with 120 laboratories in Italy and other European countries, China, Japan, India, New Zealand, and the United States. Dr. De Flora has served on the editorial board of 16 scientific journals and has received many awards and honors including the Food, Nutrition, and Chronic Disease Fund from the Michigan State University (May 2002), the Sobels Award (Island of Kos, Greece, 2005), and dedication of 10th ICMAA (Guarujà, Brazil, 2010).

Sean Hays
Summit Toxicology

Sean Hays is the President and founder of Summit Toxicology, a toxicology and risk assessment consulting firm headquartered in Colorado. He received a B.S. in biomedical engineering from Texas A&M University, an M.S. in Physiology from the University of Vermont, an M.S. in chemical engineering from Colorado State University, and a Ph.D. in Toxicology from the University of Utrecht. Dr. Hays has been a consultant since 1995 and specializes in conducting exposure assessments, deriving acceptable exposure limits (i.e., reference doses and reference concentrations, cancer slope factors, permissible exposure limits, and minimal risk levels), and developing pharmacokinetic (PK), physiologically based pharmacokinetic (PBPK), and pharmacodynamic (PD) models for drugs and chemicals. Dr. Hays is the originator of the concept of the Biomonitoring Equivalent (BE), a screening tool that allows for interpretation of biomonitoring data in a public health risk context.